Future needs for clinical trials in autosomal dominant polycystic kidney disease
2026-03-24
Karla M. Márquez-Nogueras, Ivana Y. Kuo, Arlene B. Chapman
Nature Reviews Nephrology, Published online: 24 March 2026; doi:10.1038/s41581-026-01070-4 Autosomal dominant polycystic kidney disease is the most common inherited cause of kidney failure, yet therapeutic interventions remain limited. Scientific advances are undoubtedly catalysing the development of new interventions; however, consideration of randomized clinical trials that have been conducted to date provide important insights that should guide the development of future trials.